Raw Materials Risk Management in GMP Facilities: Avoiding GMP Non-Compliance Due to Raw Material Issues

Why Should You Attend:

This webinar is a must for GMP facilities or facilities trying to be GMP compliant irrespective of the kind of product manufactured: drug, biologic, diagnostic kit, medical device or dietary supplements. This presentation will help you understand the current requirements for raw material management with tips about practical implementation. We would discuss the FDA’s expectations from GMP facilities regarding raw material vendor selection, measures for assuring acceptable quality of material supplied, expectations from quality control and documentation processes, and training requirements, with case studies. Attendees will be able to use the training to evaluate existing programs and get tips about assuring compliance with FDA requirements. Impact on compliance with other regulatory requirements in other parts of the world will also be discussed.

Areas Covered in the Webinar:

• FDA requirements for raw material management at GMP facilities
• Common risk management practices
• Vendor selection and validation requirements
• Product specific raw material issues: chemical, biologic and botanical raw materials
• Suggested quality control measures
• FDA’s common findings and possible resolutions
• Trends in FDA inspection of raw material processes
• Regional and multinational raw material providers
• Raw material risk management in the global setting

Who Will Benefit:

• Compliance/regulatory affairs professionals
• Managers of GMP facilities
• Supply chain managers
• QC and analytical methods scientists and managers
• QA directors, managers and personnel
• Purchasing and materials control managers
• GMP site personnel
• Senior managers of companies using CMOs
• People investing in FDA-regulated product development projects

Instructor Profile:

Dr. Mukesh Kumar is a Washington DC-based consultant in regulatory affairs and quality assurance for manufacturers and developers of FDA-regulated products. He leads the regulatory affairs and quality assurance departments at Amarex, a full service pharmaceutical product development company based in Germantown, MD. His key expertise is in regulatory affairs, clinical trials and multi-national project management for medicinal and diagnostic products. He has been involved in about more than 100 clinical trials in more than 40 countries, has made hundreds of US FDA submissions, and arranged a number of meetings with the US FDA. In addition, he has had made regulatory submission in the EU, Taiwan, Korea, China, Canada, countries in South America, Australia, and India. He has conducted GCP, GLP, GMP and GACP audits in the US and several countries in Europe, North and South Americas and Asia.

Dr. Kumar has conducted numerous training workshops in FDA compliance related issues. He has authored numerous articles in peer-reviewed journals. He is a well-known expert in global regulatory affairs and has been an invited speaker in several professional and academic organizations worldwide. Dr. Kumar is a PhD in Biochemistry and is a certified regulatory affairs professional by the Regulatory Affairs Professional Society, USA.

Topic Background:

Almost all FDA findings during GMP inspections include raw material related issues and most FDA warning letters to GMP facilities cite violations in raw material management. FDA's GMP inspectors pay special attention to the way raw materials are sourced, handled, controlled, used, and accounted for at a given facility. There is mention of raw material management in GMP regulations for all kinds of FDA regulated products – drugs, biologics, medical devices, diagnostic kits, dietary supplements and veterinary products. Raw material management is particularly challenging because it is mostly based on performance of independent vendors out of direct control of the GMP facility. Hence it is important for all GMP manufactures to implement robust methods for raw material risk management.

Follow us :